trimegestone Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Trimegestone, sold under the brand names Ondeva and Totelle among others, is a progestin medication which is used in menopausal hormone therapy and in the prevention of postmenopausal osteoporosis. It was also under development for use in birth control pills to prevent pregnancy, but ultimately was not marketed for this purpose. The medication is available alone or in combination with an estrogen. It is taken by mouth.   Wikipedia

Chemistry

  • SMILES: C[C@H](O)C(=O)[C@@]1(C)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3CC[C@@]21C
  • InChIKey: JUNDJWOLDSCTFK-MTZCLOFQSA-N
  • Mol. Mass: 342.48
  • ALogP: 4.15
  • ChEMBL Molecule:
    trimegestone  
More Chemistry

Pharmacology

Alternative names

17-(2-hydroxy-1-oxopropyl)-17-methylestra-4,9-dien-3-one | 21-hydroxypromegestone | ru 27987 | ru-27987 | ru 27988 | ru-27988 | trimegeston | trimegestone | trimegestone, (17beta(r))-isomer

Organizations (4)

Research & Development (4)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (4)

Approved Indications (1)


 

Menopause

Experimental Indications - Clinical Trial Phases 1-4 (4)


 

Menopause ()

Postmenopause (Phase 4)

Pregnancy (Phase 1)

Vasomotor System (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial Organizations: 4

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue